Tag: Non-ergot D2/D3 dopamine agonist

  • Ropinirole

    Non-ergot D2/D3 dopamine agonist

    A non-ergot indolone D2/D3 dopamine receptor agonist; alternative to pramipexole in Parkinson disease and restless legs syndrome.

    Abstract

    Ropinirole (4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; CAS 91374-21-9; molecular formula C16H24N2O; molecular weight 260.38) is a non-ergot indolone D2/D3 dopamine receptor agonist developed at SmithKline Beecham (now GSK) and approved by the FDA in 1997 under the trade name Requip. Affinity is approximately balanced at D2 and D3 (Ki approximately 24 and 30 nM respectively), distinguishing it from the more D3-preferring pramipexole. Plasma half-life is approximately 6 hours; metabolism is via CYP1A2. Approved for Parkinson disease and restless legs syndrome. Comparable efficacy and tolerability to pramipexole in head-to-head studies, with similar impulse control disorder risk. Used as an alternative reference non-ergot dopamine agonist.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.